Astrazeneca

FromAstraZeneca ([email protected])
Subject (41)Saphnelo met primary endpoint in TULIP-SC
Preheader (150)Saphnelo self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysi
Typography
Arial
Colors
Text Analysis
Body Words163
Subject Words6
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images6
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px806 px
X-Spam Score2.1
Preheader OptimizedNo
Timing
Day of WeekWednesday
TimeEvening

Saphnelo met primary endpoint in TULIP-SC

Saphnelo self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysi
Saphnelo met primary endpoint in TULIP-SC